CD274 and cervical carcinoma: Patients with PD-L1-positive cervical cancer experienced significantly longer progression-free survival (PFS) when pembrolizumab was added to standard therapy (10.5 months vs. 8.2 months, HR 0.58 [0.47–0.71], p < 0.001) [5].